CHEK2 1100delC germline mutation: A frequency study in hereditary breast and colon cancer Brazilian families

Arquivos de Gastroenterologia

Volumn 49, Issue 4, 2012, Pages 273-278

  Abud, Jamile ^a,b   Prolla, João Carlos ^a   Rossi, Cristina ^a,b   Palmero, Edenir Inez ^c   Vargas, Fernando Regla ^d   Nunes, Luciana Neves ^a   Achatze, Maria Izabel ^e   Moreira, Miguel Ångelo ^d   Ashton Prolla, Patricia ^a,b,f   Izetti, Patricia ^b   Cossio, Silvia Liliana ^b,f  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c BARRETOS CANCER HOSPITAL   (Brazil)

^d INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^e A C CAMARGO CANCER CENTER   (Brazil)

^f INAGEMP Instituto Nacional de Genetica Medica Populacional   (Brazil)

Author keywords

Breast neoplasms, genetics; Colonic neoplasms, genetics; Genetic predisposition to disease; Protein serine threonine kinase, genetics

Indexed keywords

CHECKPOINT KINASE 2;

ADULT; ARTICLE; BRAZIL; BREAST CANCER; CANCER RISK; COLON CANCER; FAMILIAL CANCER; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; MALE;

BRAZIL; BREAST NEOPLASMS; COLONIC NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GERM-LINE MUTATION; HUMANS; MALE; MIDDLE AGED; PEDIGREE; PHENOTYPE; POLYMERASE CHAIN REACTION; PROTEIN-SERINE-THREONINE KINASES;

EID: 84874289496     PISSN: 00042803     EISSN: 16784219     Source Type: Journal    
DOI: 10.1590/S0004-28032012000400008     Document Type: Article

References (43)

1. Allain DC. Genetic counseling and testing for common hereditary breast cancer syndromes: a paper from the 2007 William Beaumont hospital symposium on molecular pathology. J Mol Diagn. 2008;10:383-95.
2. Antoni L, Sodha N, Collins I, Garrett M. CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin? Nat Rev Cancer. 2007;7:925-36. (Pubitemid 350165855)
3. Bell DW, Varley JM, Szydlo TE, Kang DH. Wahrer DC, Shannon KE, Lubra-tovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE, Haber DA. Heterozygous germ line hCH K2 mutations in Li-Fraumeni syndrome. Science. 1999;286:2528-31.
4. Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, Jones PH, Binchy A, Crowther D, et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 1994;54:1298-304. (Pubitemid 24108072)
5. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-57. (Pubitemid 28521189)
6. The CHEK2 - Breast Cancer Case-Control Consortium CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cases and 9,065 controls from 10 studies Am J Hum Genet. 2004;74:1175-82.
7. Chompret A, Brugieres L, Ronsin M, Gardes M, Dessarps-Freichey F, Abel A, Hua D, Ligot L, Dondon M, Bressac-de Paillerets B, FrebourgT, Lemerle J, Bonalti-Pellie C, Feunteun J. p53 germline mutations in childhood cancers and cancer risk for carrier individuals Br J Cancer. 2000;82:1932-7. (Pubitemid 30326453)
8. Chompret A, Abel A, Stoppa-Lyonnet D, Brugiéres L, Pages S, Feunteun J, Bonaïti-Pellié C. Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet. 2001;38:43-7. (Pubitemid 32102322)
9. Cybulski C, Gôrski B, Huzarski T, Masojc B, Mierzejewski M, Debniak T, Teodorczyk U, Byrski T, Gronwald J, Matyjasik J, Zlowocka E, Lenner M, Grabowska E, Nej K, Castaneda J, Medrek K, Szymahska A, Szymahska J, Kurzawski G, Suchy J, Oszurek O, Witek A, Narod S, Lubihski J. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet. 20O4;75:l 131-5. (Pubitemid 39532081)
10. Cybulski C, Wokotorczyk D, Huzarski T, Byrski T, Gronwald J, Gôrski B, Debniak T, Masojh B, Jakubowska A, Gliniewicz B, Sikorski A, Stawicka M, Godlewski D, Kwias Z, Antczak A, Krajka K, Lauer W, Sosnowski M, Sikorska-Radek P, Bar K, Klijer R, Zdrojowy R, Malkiewicz B, Borkowski A, Borkowski T, Szwiec M, Narod SA, Lubihski J. A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer. J Med Genet. 2006;43:863-6. (Pubitemid 44787112)
11. Dana-Faber Cancer Institute Lynch syndrome (hereditary nonpolyposis colorectal cancer. PREMMI,2,6 model: prediction model for MLH1, MSH2, and MSH6 gene mutations Available from: http://dana-farber.prod.dfcidev.org/pat/cancer/ gastrointestinal/crc-calculator/default.asp
12. de Bock GH, Schutte M, Krol-Warmerdam EMM, Seynaeve C, Blom J, Bre-kelmans CTM, Meijers-Heijboer H, van Asperen CJ, Cornelisse CJ, Devilee P, Tollenaar RA, Klijn JG. Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2. 1100delC variant. J Med Genet. 2004;41:731-5. (Pubitemid 39389288)
13. Dong X, Wang L, Taniguchi K, Wang X, Cunningham JM, McDonnell SK, Qian C, Marks AF, Slager SL, Peterson BJ, Smith DI, Cheville JC, Blute ML, Jacobsen SJ, Schaid DJ, Tindall DJ, Thibodeau SN, Liu W. Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet. 2003;72:270-80. (Pubitemid 36194238)
14. Frank TS, Deflenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, Critchfield GC. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002;20:1480-90. (Pubitemid 34260526)
15. Isinger A, Bhat M, Borg A, Nilbert M. CHEK2 1100delC in patients with metachronous cancers of the breast and the colorectum. BMC Cancer. 2006,6:64.
16. Johnson N, Fletcher O, Naceur-Lombardelli C, dos Santos Silva I, Ashworth A, Peto J. Interaction between CHEK2. 1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study. Lancet. 2005;366:1554-7. (Pubitemid 41540113)
17. Kilpivaara O, Vahteristo P, Falck J, Syrjakoski K, Eerola H, Easton D, Bartkova J, Lukas J, Heikkila P, Aittomaki K, Holli K, Blomqvist C, Kallioniemi OP, Bartek J, Nevanlinna H. CHEK2 variant 1157T may be associated with increased breast cancer risk. Int J Cancer. 2004; 111:543-7. (Pubitemid 39045321)
18. Kilpivaara O, Alhopuro P, Vahteristo P, Aaltonen LA, Nevanlinna, H. CHEK2 I157T associates with familial and sporadic colorectal cancer. J Med Genet. 2006;43:e34.
19. Koppert LB, Schutte M, Abbou M, Tilanus H, Dinjens WN. The CHEK-2(*)1100delC mutation has no major contribution in oesophageal carcinogenesis. Br J Cancer. 2004;90:888-91. (Pubitemid 38406602)
20. Lee SB, Kim SH, Bell DW, Wahrer DC, Schiripo TA, Jorczak MM, Sgroi DC, Garber JE, Li FP, Nichols KE, Varley JM, Godwin AK, Shannon KM, Harlow E, Haber DA. Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni syndrome. Cancer Res. 2001;61:8062-7. (Pubitemid 33091590)
21. Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW. A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988;48:5358-62.
22. Lipton L, Thomas HJ, Eeles RA, Houlston RS, Longmuir M, Davison R, Hodgson SV, Murday VA, Norbury CG, Taylor C, Tomlinson IP. Apparent Mendelian inheritance of breast and colorectal cancer: chance, genetic heterogeneity or a new gene? Fam Cancer. 2001; 1:189-95.
23. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGul Tog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR; CHEK2-Breast Cancer Consortium. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nature Genet. 2002;31:55-9.
24. Meijers-Heijboer H, Wijnen J, Vasen H, Wasielewski M, Wagner A, Hollestelle A, Elstrodt F, van den Bos R, de Snoo A, Fat GT, Brekelmans C, Jagmohan S, Franken P, Verkuijlen P, van den Ouweland A, Chapman P, Tops C, Möslein G, Burn J, Lynch H, Klijn J, Fodde R, Schutte M. The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am J Hum Genet. 2003;72:1308-14. (Pubitemid 36530019)
25. Meijers-Heijboer H, Wijnen J, Vasen H, Wasielewski M, Wagner A, Hollestelle A, Elstrodt F, van den Bos R, de Snoo A, Fat GT, Brekelmans C, Jagmohan S, Franken P, Verkuijlen P, van den Ouweland A, Chapman P, Tops C, Möslein G, Burn J, Lynch H, Klijn J, Fodde R, Schutte M. The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am J Hum Genet. 2003;72:1308-14. (Pubitemid 36530019)
26. Narod S, Lynch H. CHEK2 mutation and hereditary breast cancer. J Clin Oncol. 2007;25:6-7. (Pubitemid 350003043)
27. Naseem H, Boylan J, Speake D, Leask K, Shenton A, Lalloo F, Hill J, Trump D, Evans DG. Inherited association of breast and colorectal cancer: limited role of CHEK2 compared with high-penetrance genes. Clin Genet. 2006;70:388-95. (Pubitemid 44515640)
28. National Comprehensive Cancer Network - NCCN. Practice guidelines for detection, prevention, & risk reduction. Genetic/familial high-risk assessment: breast and ovarian [Internet]. 2010. Available from: http://www.nccn.org/professionals/physician-gls/f-guidehnes.asp#genetic- screening.
29. Nevanlinna H, Bartek J. The CHEK2 gene and inherited breast cancer susceptibility. Oncogene. 2006;25:5912-9. (Pubitemid 44453447)
30. Olivier M, Goldgar D, Sodha N, Ohgaki H, Kleihues P, Hainaut P, Eeles R. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 2003;63:6643-50. (Pubitemid 37322942)
31. Ruijs MW, Broeks A, Menko FH, Ausems MG, Wagner A, Oldenburg R, Meijers-Heijboer H, van't Veer LJ, Verhoef S. The contribution of CHEK2 to the TP53-negative Li-Fraumeni phenotype. Hered Cancer Clin Pract. 2009;7:4.
32. Sánchez de Abajo A, de la Hoya M, Godino J, Furió V, Tosar A, Pérez-Segura P, Díaz-Rubio E, Caldés T. The CHEK2 1100delC allele is not relevant for risk assessment in HNPCC and HBCC Spanish families. Fam Cancer. 2005;4:183-6. (Pubitemid 40897821)
33. Schutte M, Seal S, Barfoot R, Meijers-Heijboer H, Wasielewski M, Evans DG, Eccles D, Meijers C, Lohman F, Klijn J, van den Ouweland A, Futreal PA, Nathan-son K L, Weber BL, Easton DF, Stratton M R, Rahman N; Breast Cancer Linkage Consortium. Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. Am J Hum Genet. 2003;72:1023-8. (Pubitemid 36403321)
34. Shaag A, Walsh T, Renbaum P, KirchhofT T, Nafa K, Shiovitz S, Mandell JB, Welcsh P, Lee MK, Ellis N, Offit K, Levy-Lahad E, King MC. Functional and genomic approaches reveal an ancient CH EK2 allele associated with breast cancer in the Ashkenazi Jewish population. Hum Mol Genet. 2005;14:555-63. (Pubitemid 40277471)
35. Sodha N, Houlston RS, Williams R, Yuille MA, Mangion J, Eeles RA. A roubust method for detecting CHK2/RAD53 mutation in genomic DNA. Human Mutation. 2002;19:173-7. (Pubitemid 34121808)
36. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, adopted on February 20, 1996. J Clin Oncol. 1996;14:1730-6.
37. University of Pennsylvania. Abramson Cancer Center. Couch modifies mutation prediction model [Internet]. 2011. Available from: http://www.afcri. upenn.edu/ itacc/penn2/
38. Vahteristo P, Tamminen A, Karvinen P, Eerola H, Eklund C, Aaltonen LA, Blomqvist C, Aittomaki K, Nevanlinna H. p53, CHK2, and CHK1 genes in families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition. Cancer Res. 2001;61:5718-22. (Pubitemid 32769084)
39. Vahteristo P, Bartkova J, Eerola H, Syrjákoski K, Ojala S, Kilpivaara O, Tamminen A, Kononen J, Aittomáki K, Heikkilá P, Holli K, Blomqvist C, Bartek J, Kallioniemi OP, Nevanlinna H. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet. 2002;71:432-8. (Pubitemid 34800260)
40. Vasen HF. Clinical description of the Lynch syndrome [hereditary nonpolyposis colorectal cancer (HNPCC)]. Fam Cancer. 2005;4:219-25. (Pubitemid 41242190)
41. Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernjkova S, Foretova L, Soucek P, King MC. Spectrum of mutations in BRCA 1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA. 2006;295:1379-88.
42. Wasielewski M, Vasen H, Wijnen J, Hooning M, Dooijes D, Tops C, Klin JGM, Meijers-Heijboer H, Schutte M. CHEK2 1100delC is a susceptibility allele for HNPCC-related colorretal cancer. Clin Cancer Res. 2008;14:4989-94.
43. Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG. CHEK-2.*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol. 2008;26:542-8. (Pubitemid 351264346)